SCHEMBL21610044

SCHEMBL21610044

Cc1cccc(Nc2nc3nonc3nc2N/N=C/c2cc3c(cc2[N+](=O)[O-])OCO3)c1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.55
MAPT P10636 13/20 0.51
ALDH1A1 P00352 9/20 0.51
NPSR1 Q6W5P4 2/20 0.51
BIRC5 O15392 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
TP53 P04637 1/20 0.49
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
KDM4E B2RXH2 5/20 0.47
PKM P14618 1/20 0.47
APOBEC3A P31941 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
POLB P06746 3/20 0.47
LMNA P02545 2/20 0.47
PABPC1 P11940 1/20 0.47
EIF4H Q15056 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419647 0.86 GAA (0.52) GAAMAPTALDH1A1NPSR1SMN1; SMN2
SCHEMBL6419651 0.86 GAA (0.52) GAAMAPTALDH1A1NPSR1SMN1; SMN2
SCHEMBL8265099 0.81 MAPT (0.55) GAAMAPTALDH1A1BIRC5SMN1; SMN2
SCHEMBL3046026 0.80 BIRC5 (0.53) GAAMAPTALDH1A1BIRC5SMN1; SMN2
SCHEMBL6416845 0.80 BIRC5 (0.53) GAAMAPTALDH1A1BIRC5SMN1; SMN2
SCHEMBL3046030 0.80 BIRC5 (0.53) GAAMAPTALDH1A1BIRC5SMN1; SMN2
SCHEMBL6507461 0.75 BIRC5 (0.67) GAAMAPTALDH1A1NPSR1BIRC5
SCHEMBL6507458 0.75 BIRC5 (0.67) GAAMAPTALDH1A1NPSR1BIRC5
SCHEMBL13905878 0.73 BIRC5 (0.52) GAAMAPTALDH1A1NPSR1BIRC5
SCHEMBL8265004 0.73 GAA (0.56) GAAMAPTALDH1A1NPSR1BIRC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10517871-B2 Survivin-targeting anti-tumor agents and uses thereof INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2019-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10517871-B2 Survivin-targeting anti-tumor agents and uses thereof XIAP, BIRC5, BIRC2 GAA 2017/4885MAPT 2699/4885ALDH1A1 2938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.